ERBB2 and breast cancer: HER2 mRNA expression levels were found to be significantly associated with a better response to HER2-targeted drugs in several clinical trials in HER2-positive BC patients treated with neoadjuvant anti-HER2 drugs [12,13,14,15,16,17,18].